The clinical applicability of the other three candidate ovarian cancer markers included in this study, B7-H4 (Simon et al, 2007a, 2007b), Reg-IV and Spondin-2 (Simon et al, 2007b), is still unknown. This evidence concerns the gene REG4 and ovarian cancer.